Which Peptides Are Legal Again in 2026? The Full FDA List

Which Peptides Are Legal Again in 2026?

Fourteen peptides are returning to legal compounding status in 2026 after HHS Secretary Robert F. Kennedy Jr. announced on February 27, 2026 that the FDA would reclassify them from Category 2 (restricted) back to Category 1. This means licensed compounding pharmacies can once again prepare these compounds under a physician's prescription. If you have been sourcing peptides from grey-market research chemical vendors, this changes the game. Legal, pharmaceutical-grade access through a prescribing physician is the safest and most reliable route, and it is opening back up.

This guide covers every peptide affected by the reclassification, what each one does, who uses it, and what the return to Category 1 actually means in practice. We also cover the compounds that remain restricted and why.

What Happened: The FDA Category System Explained

In 2023, the FDA placed 19 peptides on its Category 2 list for bulk drug substances. Category 2 means a compound cannot be used by 503A compounding pharmacies, which are the pharmacies that prepare custom prescriptions for individual patients. This effectively cut off legal access for anyone using these peptides through a clinic or prescribing doctor.

The backlash was significant. Patients who relied on compounds like BPC-157 for injury recovery or Thymosin Alpha-1 for immune support lost access overnight. Clinics that had been prescribing these peptides legally for years were forced to stop. The biohacking and longevity communities pushed back hard, arguing that the FDA was restricting access to compounds with decades of research and clinical use, particularly in Europe and Russia.

On February 27, 2026, Kennedy announced that 14 of those 19 peptides would move back to Category 1. Five peptides were referred to the Pharmacy Compounding Advisory Committee (PCAC) first for formal review, with the rest expected to follow. As of April 2026, the formal reclassification has not yet been published in the Federal Register, but the policy direction is clear and compounding pharmacies are preparing to resume production.

What Category 1 Actually Means

Category 1 does not mean FDA-approved. None of these peptides have gone through the full FDA drug approval process. What Category 1 means is that licensed compounding pharmacies can legally prepare them for individual patients with a valid prescription. You still need a prescribing physician. You still need a legitimate compounding pharmacy. But the legal pathway that existed before 2023 is being restored.

The 14 Peptides Returning to Category 1

Here is every peptide expected to return to legal compounding status, what it does, and who benefits most from the reclassification.

BPC-157 (Body Protection Compound)

BPC-157 is a pentadecapeptide originally isolated from human gastric juice. It is the single most researched peptide on this list for tissue repair. Preclinical studies demonstrate accelerated healing of muscle, tendon, ligament, bone, and gastrointestinal tissue through multiple mechanisms: upregulation of VEGFR2, activation of the Akt-eNOS nitric oxide pathway, enhanced collagen synthesis, and anti-inflammatory cytokine modulation. A 2025 systematic review identified 36 studies showing improved functional, structural, and biomechanical outcomes across injury models (Vasireddi et al., 2025).

UB has covered BPC-157 extensively. If you are new to it, start with our BPC-157 dosing protocol guide. If you are deciding between delivery methods, see BPC-157 oral vs injectable. Athletes should be aware that BPC-157 is banned by WADA regardless of its FDA compounding status.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring protein involved in cell migration, blood vessel formation, and tissue repair. Where BPC-157 works locally at the injection site, TB-500 operates systemically. It upregulates actin, which allows cells to migrate to injury sites faster, and promotes angiogenesis to support new blood vessel growth in damaged tissue.

TB-500 is particularly valued for soft tissue injuries, joint recovery, and flexibility. Our TB-500 complete guide covers the full science. For dosing specifics, see the TB-500 dosage protocol. Many practitioners combine it with BPC-157 in what we call the Wolverine Stack for compounded healing effects.

CJC-1295

CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue that stimulates the pituitary gland to produce and release more growth hormone. It is typically used in its DAC (Drug Affinity Complex) form, which extends its half-life to roughly a week, allowing for less frequent dosing. CJC-1295 is one of the first five peptides referred to the PCAC for formal review and is expected to be among the earliest to return to pharmacy shelves.

Primary use cases include improved sleep quality, enhanced recovery, lean body composition, and anti-ageing protocols. It is almost always paired with Ipamorelin for synergistic effects.

Ipamorelin

Ipamorelin is a growth hormone secretagogue that triggers GH release from the pituitary without significantly raising cortisol or prolactin levels, which distinguishes it from older secretagogues like GHRP-2 and GHRP-6. This cleaner side-effect profile is exactly why it is returning to Category 1 while GHRP-2 and GHRP-6 may not.

Combined with CJC-1295, the CJC/Ipamorelin stack is the most widely prescribed growth hormone peptide protocol in anti-ageing and performance medicine. It supports deeper sleep, faster recovery, and improved body composition without the risks associated with exogenous growth hormone.

Thymosin Alpha-1

Thymosin Alpha-1 is an immune-modulating peptide that enhances T-cell function, dendritic cell maturation, and natural killer cell activity. Unlike most peptides on this list, Thymosin Alpha-1 is actually an approved pharmaceutical in over 35 countries under the brand name Zadaxin, primarily for hepatitis B and C treatment and as an adjunct in cancer immunotherapy.

Its removal from the Category 2 list is particularly significant for patients with chronic infections, autoimmune conditions, and those undergoing immunosuppressive treatments. It was one of the first five peptides referred to the PCAC.

AOD-9604

AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) that targets fat metabolism without the broader effects of full-length GH. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without affecting blood sugar or promoting tissue growth.

AOD-9604 is used in body composition protocols, particularly for stubborn visceral and subcutaneous fat. It was one of the first five peptides sent to the PCAC for formal review and has already received TGA approval in Australia as an anti-obesity compound, which strengthens its case for reclassification.

Selank

Selank is a synthetic analogue of the naturally occurring immunopeptide tuftsin, developed at the Institute of Molecular Genetics in Russia. It modulates GABA, serotonin, and dopamine pathways, producing anxiolytic effects comparable to benzodiazepines without sedation, cognitive impairment, or dependence risk. Selank also enhances BDNF expression, supporting neuroplasticity and memory consolidation.

Selank was one of the first five peptides referred to the PCAC and is expected to be among the earliest reclassified. Our Selank complete guide covers the research, and our Semax vs Selank comparison helps you decide which neuropeptide fits your protocol.

Semax

Semax is a synthetic analogue of ACTH(4-10), also developed in Russia, where it has been an approved pharmaceutical since 2011. It enhances cognitive function through BDNF and NGF upregulation, improves cerebral circulation, and has neuroprotective properties. Unlike stimulants, Semax improves focus and mental clarity without jitteriness, tolerance buildup, or crash.

Semax is primarily used as a nasal spray, making it one of the most accessible peptides for daily cognitive enhancement protocols. Read our Semax complete guide for the full breakdown of dosing, mechanisms, and practical application.

GHK-Cu (Copper Peptide)

GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Its concentration declines significantly with age, dropping from around 200 ng/ml at age 20 to 80 ng/ml by age 60. It promotes wound healing, collagen synthesis, skin remodelling, and has demonstrated anti-inflammatory and antioxidant properties in research.

GHK-Cu is widely used in both topical skincare products and injectable protocols. The injectable form is returning to compounding access, which matters for practitioners using it in regenerative medicine contexts beyond cosmetic application.

KPV

KPV is a tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) with potent anti-inflammatory properties. It inhibits NF-kB signalling, one of the master regulatory pathways for inflammation. Unlike full-length alpha-MSH, KPV does not cause skin pigmentation changes.

KPV is primarily used for gut inflammation protocols, including inflammatory bowel conditions. It is often combined with BPC-157 for gut health in comprehensive GI healing stacks. Its return to compounding status is significant for patients who were using it under clinical supervision for chronic gut inflammation.

MOTS-c

MOTS-c is a mitochondrial-derived peptide encoded by the mitochondrial genome. It activates AMPK, the cellular energy sensor, and enhances glucose uptake and fatty acid oxidation independently of insulin. Research suggests it improves metabolic flexibility, exercise capacity, and may play a role in longevity pathways.

MOTS-c is increasingly used in metabolic health and longevity protocols. It represents a newer class of peptides that target cellular energy metabolism rather than hormonal pathways, making it particularly interesting for researchers and clinicians focused on healthspan extension.

Dihexa

Dihexa is a synthetic peptide derived from angiotensin IV that crosses the blood-brain barrier and enhances hepatocyte growth factor (HGF) signalling in the brain. It is estimated to be approximately 10 million times more potent than BDNF at promoting synaptic connections. Research has focused on its potential for cognitive enhancement and neurodegenerative conditions.

Dihexa is one of the more experimental compounds on this list. Its extreme potency and limited human safety data make it one that should only be explored under close medical supervision. The return to compounding status will allow clinical research to proceed more readily.

Kisspeptin-10

Kisspeptin-10 is a neuropeptide that plays a central role in the hypothalamic-pituitary-gonadal axis. It stimulates gonadotropin-releasing hormone (GnRH), which in turn triggers luteinising hormone (LH) and follicle-stimulating hormone (FSH) release. Research applications include fertility treatment, hypogonadism assessment, and hormonal regulation.

Kisspeptin-10 is primarily relevant for reproductive medicine and hormone optimisation protocols. Its reclassification restores a tool that fertility clinics and endocrinologists were using before the 2023 restrictions.

DSIP (Delta Sleep-Inducing Peptide)

DSIP is a neuropeptide that modulates sleep architecture, particularly slow-wave (deep) sleep. It was first identified in 1977 from the cerebral venous blood of rabbits during induced sleep. Beyond sleep, research suggests it modulates stress responses, cortisol regulation, and may have analgesic properties.

DSIP is used in sleep optimisation protocols, particularly for individuals who struggle with deep sleep quality rather than sleep onset. Its return to compounding access provides a non-benzodiazepine, non-habit-forming option for practitioners working with sleep-disrupted patients.

Peptides Expected to Remain Restricted

Approximately five peptides from the original 19 are expected to remain on Category 2. As of April 2026, the formal FDA list has not been published, and sources disagree on the exact compounds staying restricted. Based on available reporting, the most likely candidates to remain restricted include Melanotan II (linked to melanoma risk and cardiovascular side effects), LL-37/Cathelicidin (limited human safety data), PEG-MGF (minimal clinical evidence), and potentially Cerebrolysin and Follistatin 344.

The situation with GHRP-2 and GHRP-6 is less clear. Some sources list them as returning to Category 1 alongside CJC-1295 and Ipamorelin, while others suggest they may remain restricted due to their impact on cortisol and prolactin levels. We will update this section when the FDA publishes its formal reclassification.

What This Means for You Practically

The reclassification changes how you can legally access these peptides, not whether they work. If you are already using compounds like BPC-157 or TB-500 sourced from research chemical vendors, the science does not change. What changes is the quality assurance and legal standing of your supply.

Compounding Pharmacy vs Research Chemical Vendors

A compounding pharmacy operates under state board of pharmacy oversight, uses USP-grade ingredients, follows sterility protocols, and requires a valid prescription. A research chemical vendor operates in a legal grey area, sells products labelled "not for human consumption," and has no regulatory oversight of purity or sterility. The reclassification moves these peptides back into the regulated pharmacy pathway, which is unequivocally the safer supply chain.

What You Need to Get a Prescription

You will need a prescribing physician, nurse practitioner, or other licensed prescriber who is familiar with peptide therapy. This typically means a functional medicine doctor, anti-ageing clinic, or integrative health practitioner. Many telehealth platforms are already preparing to offer peptide prescriptions once the formal reclassification takes effect. Insurance does not cover compounded peptides, so expect to pay out of pocket.

Timeline

Five peptides (CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, and Selank) have already been referred to the PCAC for formal review. The remaining nine are expected to follow through Q2 and Q3 of 2026. Practical availability through pharmacies will expand as each compound completes the review process. If you are currently on a protocol using any of these compounds, talk to your prescriber now about transitioning to a compounding pharmacy source as they become available.

How This Affects Peptide Stacks and Protocols

The reclassification is particularly significant for multi-peptide protocols that combine compounds across different categories. Some of the most popular stacks are now fully within the legal compounding pathway.

The Wolverine Stack (BPC-157 + TB-500) is the most widely used healing protocol in the biohacking community. Both compounds are returning to Category 1, which means a physician can prescribe this combination from a single compounding pharmacy with verified purity and proper sterility controls.

The CJC-1295 + Ipamorelin growth hormone stack is the most prescribed peptide combination in anti-ageing medicine. Both compounds are among the first five referred for formal review. The nootropic stack of Semax and Selank also falls entirely within the reclassified group.

For gut health protocols combining BPC-157 with KPV, both compounds are returning. Practitioners running BPC-157 alongside TRT protocols will now have compounding pharmacy access for the peptide component.

The Bigger Picture

This reclassification represents the most significant regulatory shift for peptide access since the original 2023 restrictions. It signals a policy direction that favours patient access to compounds with established research profiles, even when those compounds lack full FDA drug approval.

For the biohacking and longevity community, it validates what practitioners have been arguing for years: that restricting access to well-researched peptides with strong safety profiles was an overreach. For patients, it means safer, more reliable access through legitimate medical channels.

We will continue updating this guide as the formal reclassification is published. If you are new to peptides, start with our guides on how to reconstitute peptides and the best peptides for men over 40 for foundational knowledge before diving into specific compounds.